News


49 - 60 of 103 items

New nano-based treatment for brain cancer shows promise

New nano-based treatment for brain cancer shows promise

Friday, 12 de November de 2021

Current treatments for glioblastoma multiforme, both the most prevalent and the deadliest form of brain cancer, are woefully ineffective. TargetGBM has developed a nanotherapy which can cross the blood-brain barrier and selectively target tumour cells in vitro.The EU-funded TargetGBM project has developed nanoparticles covered with a special coating to prevent them from entering other cells and with molecules that selectively target tumour cells. Crucially, these nanoparticles can enter cells in the blood-brain barrier and so could potentially also cross it.

Innovative EU research targets breast cancer

Innovative EU research targets breast cancer

Monday, 8 de November de 2021

With our attention focused on the global pandemic over the past 2 years, it’s been easy to overlook the fact that other health crises continue in the background. Surgeries have gone unperformed, treatments discontinued, and diagnoses not made. In the wake of the pandemic, exhausted medics will face a backlog of cases made worse by this delay. There is no doubt that among these patients there will be many cases of breast cancer, the focus of our special feature.

The seven COVID-19 symptoms to look out for

The seven COVID-19 symptoms to look out for

Monday, 8 de November de 2021

A team of researchers supported in part by the EU-funded EXPANSE project have now identified a set of seven symptoms that, when considered together, maximise detection of COVID-19 in the community. Their findings have been published in the peer-reviewed open-access journal ‘PLOS Medicine’.

Breast cancer predisposition genes exposed

Breast cancer predisposition genes exposed

Monday, 8 de November de 2021

Scientists know that a subset of genes are linked to familial breast cancer. However, this link has yet to be clearly determined or ruled out for many newly emerging genes. The FBC predisposition project aims to clear up remaining doubts.

Bioelectronics offers hope for spinal cord injuries

Bioelectronics offers hope for spinal cord injuries

Friday, 5 de November de 2021

Bioelectrical scaffolds are implants designed to aid tissue restoration. They hold great potential for the reparation of damaged nervous systems, in part because the chemical and electrical stimuli they provide could facilitate cell regeneration and drive neuronal activity, aiding recovery. This could transform the lives of people who have suffered brain and spinal cord injury, and found their quality of life severely curtailed.

Commission establishes portfolio of 10 most promising treatments for COVID-19

Commission establishes portfolio of 10 most promising treatments for COVID-19

Thursday, 28 de October de 2021

Delivering on a key action from the EU Strategy on COVID-19 Therapeutics, the Commission is today establishing a portfolio of 10 potential COVID-19 therapeutics. The list established is based on independent scientific advice, and focuses on COVID-19 treatment candidates that are likely to be authorised and therefore available on the European market soon. These therapeutics will bring treatment to patients across the EU as fast as possible provided that their safety and effectiveness has been confirmed by the European Medicines Agency

Innovative EU research targets breast cancer

Innovative EU research targets breast cancer

Monday, 25 de October de 2021

With our attention focused on the global pandemic over the past 2 years, it’s been easy to overlook the fact that other health crises continue in the background. Surgeries have gone unperformed, treatments discontinued, and diagnoses not made. In the wake of the pandemic, exhausted medics will face a backlog of cases made worse by this delay. There is no doubt that among these patients there will be many cases of breast cancer, the focus of our special feature.

The EU Digital COVID Certificate: a global standard with more than 591 million certificates

The EU Digital COVID Certificate: a global standard with more than 591 million certificates

Monday, 18 de October de 2021

The Commission has adopted a report on the EU Digital COVID Certificate  and its implementation across the EU. The report shows that the EU certificate has been a crucial element in Europe's response to the COVID-19 pandemic, with more than 591 million certificates generated. The certificate, which covers COVID-19 vaccination, test and recovery, facilitates safe travel for citizens, and it has also been key to support Europe's hard-hit tourism industry. 

Commission launches EU missions to tackle major challenges

Commission launches EU missions to tackle major challenges

Thursday, 30 de September de 2021

The Commission launched five new EU missions, a new and innovative way to work together and improve the lives of people in Europe and beyond. EU missions aim to tackle big challenges in health, climate and the environment, and to achieve ambitious and inspiring goals in these areas.

Healthy Lifestyle: Commission launches a European-wide campaign

Healthy Lifestyle: Commission launches a European-wide campaign

Monday, 27 de September de 2021

The Commission launched the HealthyLifestyle4All campaign to promote a healthy lifestyle for all, across generations and social groups, with the objective to improve the health and well-being of Europeans. Linking sport and active lifestyles with health, food and other policies, this two-year campaign involves civil society, non-governmental organisations, national, local and regional authorities and international bodies. All involved will implement several actions for Europeans to be more active and more mindful of their health.

Coronavirus: Commission signs contract for the supply of a monoclonal antibody treatment

Coronavirus: Commission signs contract for the supply of a monoclonal antibody treatment

Wednesday, 22 de September de 2021

The Commission has signed a joint procurement framework contract with the pharmaceutical company Eli Lilly for the supply of a monoclonal antibody treatment for coronavirus patients. This marks the latest development in this first portfolio of five promising therapeutics announced by the Commission under the EU COVID-19 Therapeutics Strategy in June 2021. The medicine is currently under rolling review by the European Medicines Agency.